BlueWind Medical System for the Treatment of Patients With OAB (NCT02299544) | Clinical Trial Compass
CompletedNot Applicable
BlueWind Medical System for the Treatment of Patients With OAB
Netherlands, United Kingdom36 participantsStarted 2015-02
Plain-language summary
BlueWind system safety and performance in treatment of patients diagnosed with overactive bladder (OAB)
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Signed written informed consent.
* Male or female aged 18 - 80.
* Patient agrees to attend all follow-up evaluations and is willing to completely and accurately fill out voiding diaries and questionnaires, and is willing to complete required exams and tests.
* Patients with overactive bladder symptoms:
* Urinary frequency greater than 8 times/24 hours AND/OR Urinary urgency leaks of at least 2 leaks on 3 day voiding diary
* Patient who has failed conservative treatment after at least 6 months of treatment
* Patients with normally functioning upper urinary tract.
* Patients with no clinical evidence of a neurological S2-S4 motor sensory deficit.
* Prior PTNS Group: Patients who have had successful PTNS treatment (successful treatment is defined as ≥50% reduction in urinary frequency, and/or ≥50% fewer incontinence episodes, or a return to normal voiding frequency \[\<8 voids/day\], based on retrospective diary review).
* De novo Patient Group: Patient who passes the BlueWind compatibility test.
Exclusion Criteria:
* Any metal implant in the area of BlueWind Medical implantation site.
* Patients who have not had stable OAB medications for at least 30 days.
* Patients who have received botulinum toxin injections within the past 6 months.
* Previous urinary incontinence surgery or implantation of artificial graft material within the last 6 months.
* Any spinal or genitourinary surgery within the last 6 months. Pelvic pain disorders
* Obvious clinically de…